Babies, children and young people's experience of healthcare: draft guidance consultation
We are listening to your views on this NICE guideline. Comments close 16 April 2021.
Search results
12 results
-
-
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s: draft guidance consultation
We are listening to your views on this NICE guideline. Comments close 14 April 2021.
-
Advocacy services for adults with health and social care needs: draft scope consultation
We are listening to your views on this NICE guideline. Comments close 22 January 2021.
-
Heart valve disease presenting in adults: investigation and management: draft guidance consultation
We are listening to your views on this NICE guideline. Comments close 29 April 2021.
-
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 20 April 2021.
-
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 20 April 2021.
-
Vaccine uptake in the general population: call for evidence
We are listening to your views on this NICE guideline. Comments close 20 April 2021.
-
Multiple sclerosis in adults: management: call for evidence
We are listening to your views on this NICE guideline. Comments close 14 April 2021.
-
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 28 April 2021.
-
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 26 April 2021.
-
Weight Management: draft scope consultation
We are listening to your views on this NICE guideline. Comments close 07 May 2021.
-
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375) [ID2710]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 28 April 2021.